<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146273">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01861886</url>
  </required_header>
  <id_info>
    <org_study_id>16972</org_study_id>
    <secondary_id>ESS505-003</secondary_id>
    <nct_id>NCT01861886</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women</brief_title>
  <official_title>A Multi-Centre Clinical Study to Evaluate the Safety and Effectiveness of the ESS505® Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and long-term (approximately one year) effectiveness of the Essure
      System for Permanent Birth Control ESS505 device in preventing pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has previously been posted by Conceptus, Inc. After acquiring Conceptus, Inc.,
      Bayer is now the sponsor of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Occurence of Pregnancy</measure>
    <time_frame>3 months post placement of ESS505</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint to be evaluated in this study is occurrence of pregnancy at the 3 month visit in women told to relay on ESS505 for contraception. Absence of pregnancy is confirmed by a urine or blood pregnancy test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One Year Effectiveness Rate</measure>
    <time_frame>12 months post ESS505 placement</time_frame>
    <safety_issue>No</safety_issue>
    <description>One year effectiveness rate; methods to calculate rates and confidence intervals will be identical to that described for the primary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the ESS505 Device Placement Procedure</measure>
    <time_frame>Day of placement of ESS505</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess severity and frequency of reported adverse events related to device placement procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Subsequent Wearing of the Device</measure>
    <time_frame>12 months post ESS505 placement</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess severity and and frequency of adverse events reported among subjects in whom one or more ESS505 inserts are placed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>ESS505</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects who sign the informed consent and meet the eligibility critieria will be scheduled for an insert placement procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESS505 (BAY1454033)</intervention_name>
    <description>bilateral insert placement, single arm, open label</description>
    <arm_group_label>ESS505</arm_group_label>
    <other_name>Essure System for Permanent Birth Control Model ESS505</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female with age range 21 to 44 years

          -  Subjects who are seeking permanent contraception

          -  Subjects with body weight within range of 40 - 136 kilograms (90-300 pounds)

          -  Subjects willing to accept the risk of pregnancy occurring while relying solely on
             the ESS505 as contraception

          -  Subjects for whom medical history and physical examination indicates bilateral viable
             and patent fallopian tubes

          -  Subjects who are able to comply with the protocol required follow-up visits (e.g., 3
             month clinic visit, and the 12-month telephone interview)

          -  Subjects who provide written informed consent prior to enrolment

          -  Subjects who have sufficient mental capability to provide clinically relevant and
             reliable feedback regarding her experience wearing the device

          -  Subjects agrees that her anonymised personal data will be made available to Study
             sponsor, requisite regional and international regulatory bodies

          -  Subjects for whom there are no contraindications for use as described in the ESS505
             Instructions for Use (IFU)

        Exclusion Criteria:

          -  Subjects with known proximal tubal occlusion in either fallopian tube

          -  Subjects who have undergone fallopian tube sterilization procedure

          -  Subjects diagnosed with unicornuate uterus

          -  Subjects diagnosed with endometrial or myometrial pathology which may prevent
             fallopian tube ostia assessment

          -  Subjects scheduled to undergo concomitant intrauterine procedures at the time of
             ESS505 placement; IUD removal is not considered a concomitant procedure

          -  Subjects suspected of being or confirmed pregnant

          -  Subjects post-partum or has undergone pregnancy termination ≤6 weeks of scheduled
             ESS505 placement

          -  Subjects diagnosed with active upper or lower pelvic infection

          -  Subjects for whom there are one or more contraindications for use as described in the
             ESS505 IFU

          -  Subjects have positive pre-procedure pregnancy test
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tiel</city>
        <zip>4002 WP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Birth control</keyword>
  <keyword>Permanent Contraception</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
